You are here » About Galderma » Company History

Global Company History

Dermatology company Galderma’s detailed timeline.  Please note that products mentioned below may be known by a different brand name or may not be available or licensed within the UK or Ireland.  Please click here for a list of products available locally:


Sharon Stone partners with Galderma in global campaign to prove natural looking results of aesthetic treatments in real life


Nestlé S.A. (Nestlé) announces the creation of Nestlé Skin Health S.A.
Galderma becomes fully owned by Nestlé S.A.
Galderma (UK) Ltd launches CalmuridPro® 


Acquisition of Swiss company Spirig AG, maker of Daylong & Excipial.
FDA approval of Mirvaso for the treatment of erythema associated with rosacea.


Galderma defines its new 3-business-strategy and a new ambition statement.
Opening of a new affiliate in China.  Cetaphil Dermacontrol is launched in 6 countries.


Acquisition of Q-Med, a Swedish company specialised in aesthetic & corrective solutions.
Emervel (dermal filler range) launch in Europe and Latin America.  Launch of Cetaphil Restoraderm.
Plant extensions in France and Canada. Differin Lotion 0.1% (acne) launch in the United States.


Launch of Azzalure (glabellar lines) and Oracea (Efracea) in Europe.


Vectical (Silkis) launch in the United-States.


Epiduo launch.
Acquisition of CollaGenex Pharmaceuticals
and its product Oracea (Efracea).
Launch of Differin 0.1% in Japan.


Licensing agreements for a botulinum toxin type A and Pliaglis (topical anesthetic).
Differin 0.3% launch.


Clobex Spray launch in the US.
Opening of the new R&D center in Sophia Antipolis, France.


Metrogel 1% (rosacea) launch in the United-States.
For the first time, Galderma ranks Number One in D class in its markets 
(source: IMS Health, IMS dataview - D class - MAT Q3 2005 - 33 countries).


Opening of a new production site in Hortolandia, Brazil.
Clobex Shampoo launch in the United-States and acquisition of Tri-Luma.


Launch of Metvix in Germany and the UK and Clobex Lotion (inflammatory skin conditions) in the US.


Licensing agreements for Tri-Luma (melasma or mask of pregnancy) and Pekiron (Loceryl Cream) in Japan.
First FDA approvals for pharmaceutical production in Montreal.


Licensing agreement for Metvix (precancerous skin lesions and skin cancer treatment).
Launch of Clindagel (anti-acne).


The Montreal production unit comes on stream.
Launch of Silkis (psoriasis) and acquisition of Capex Shampoo (seborrheic dermatitis).


Acquisition of Loceryl (fungal nail infections), developed by Laboratoires Roche, together with the Scandinavian dermatology portfolio developed by Nycomed.


Inauguration of a new R&D facility in Princeton, New Jersey, USA.
Acquisition in Brazil of Darrow’s dermatology portfolio.


UK operations established, Galderma (UK) Ltd.  Acquisition of Basotherm, a subsidiary of Boehringer. 


Acquisition of a plant belonging to Wyeth-Ayerts in Montreal, Canada, to develop a state-of-the-art manufacturing plant.


Launch of anti-acne treatment Differin, Galderma’s first home-grown dermatology product.


Galderma inaugurates its wholly-owned production plant in Alby-sur-Chéran, near Annecy in the French Alps.


Acquisition of MetroGel / Rozex to include rosacea treatments in the product portfolio.


Global organisation implemented and new affiliates opened in Canada, Germany, and Spain.


Galderma progressively takes over Alcon’s dermatology business, allowing it to focus exclusively on ophthalmology.


Galderma’s first affiliate opens for business in France, followed by a second in Italy. The International Dermatology Research Center focuses its efforts on prescription dermatology products.


Nestlé and L'Oréal form a joint venture to become the world’s leading dermatology player. Galderma is born.


L'Oréal creates its International Dermatology Research Center (CIRD) in Sophia-Antipolis, France, specialising in fundamental research into skin physiology.


Discover more about Galderma, a dermatology company providing dermatology solutions and aesthetic and corrective products internationally.

Corporate responsibility

Growing a responsible dermatological community

Discover some of the positive initiatives we are involved in across the world



We are committed

See all videos